Background: Colorectal cancer (CRC) is among the most frequent and lethal malignancies worldwide. Although great advances have been made in the treatment of CRC, prognosis remains poor. Our previous study indicated that tripartite motif-containing 14 (TRIM14) was upregulated in CRC samples. Methods: In the current study, the association between TRIM14 and CRC was investigated. Protein expression was determined by Western blotting and immunohistochemistry. Further, the biological roles of TRIM14 in CRC cell proliferation and apoptosis were explored both in vitro and in vivo. Results: We observed that increased TRIM14 expression in CRC tissues was closely related with aggressive clinicopathological characteristics and poor prognosis. TRIM14 knockdown markedly reduced proliferation and increased apoptosis in HT-29 and SW620 cells, whereas TRIM14 overexpression in LoVo cells displayed opposite results. Xenograft experiments using HT-29 cells confirmed suppression of tumor growth and induction of apoptosis upon TRIM14 knockdown in vivo. Furthermore, downregulation of TRIM14 inhibited the AKT pathway, as indicated by reduced levels of phosphorylated AKT, Bcl-2 and Cyclin D1, and elevated levels of phosphatase andtensin homology (PTEN) and p27. In addition, TRIM14 co localized with PTEN in the cytoplasm and induced PTEN ubiquitination. Moreover, PTEN overexpression significantly inhibited pro-proliferative effects of TRIM14, indicating an involvement of PTEN/AKT signaling in mediating TRIM14 functions. Conclusions: The present data demonstrate that TRIM14 overexpression promotes CRC cell proliferation, suggesting TRIM14 as an attractive therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is a highly prevalent cancer in both males and females worldwide. 1 A number of risk factors have been associated with CRC development, including old age, obesity high fat intake, red meat consumption, smoking, and lack of physical exercise. [2] [3] [4] Although great advances in screening and treatment methods have provided substantial benefits for patient outcomes, CRC remains the fourth deadliest cancer, causing approximately 700,000 deaths annually.
regulating various biological processes, such as development, innate immune response, and cancer progression. 6, 7 A member of the TRIM family, TRIM14, was first found overexpressed in human immunodeficiency virusassociated human non-Hodgkin's lymphomas. 8 Subsequent studies have shown that TRIM14 was involved in host defense against viral infections.
9,10
Recent studies have revealed aberrant expression of TRIM14 in various human cancers. For instance, reduced expression of TRIM14 and functions in tumor suppression were observed in non-small cell lung cancer. 11 In contrast, oncogenic function and elevated expression of TRIM14 were reported in osteosarcoma, 12 oral squamous cell carcinoma, 13 tongue squamous cell carcinoma , 14 and hepatocellular carcinoma. 15 Activation of the phosphoinositide 3-kinase (PI3K)/ AKT pathway, which triggers cell growth, proliferation, and motility, 16 has been related to CRC oncogenesis. 17 CRC cells overexpressing AKT displayed a highly proliferative and invasive state. 18 Phosphatase and tensin homology (PTEN), which antagonizes the effects of PI3K and ultimately inactivates the AKT pathway, 19 was found to be downregulated in CRC 20 and suppress CRC growth. 21 It has been reported that TRIM14 stimulates AKT signaling in osteosarcoma cells. 12 On the other hand, the association between TRIM14 and AKT signaling during CRC progression has not been explored. The results of our recent study 22 indicated that TRIM14
was upregulated in CRC and promoted the migration and invasion of CRC cells. In the current study, we further probed the correlation between TRIM14 expression and CRC patient prognosis, and went on to investigate the functions of TRIM14 on CRC cell proliferation and apoptosis. Moreover, we explored the involvement of PTEN/AKT signaling during this process.
Materials and methods

Patient information
The study was approved by the Ethics Committee at Yiwu Hospital, Wenzhou Medical University (Yiwu, China). Formalin-fixed, paraffin-embedded CRC samples, and matched non-cancerous tissue samples (n=74) were obtained from patients who received curative surgery at the Department of Gastroenterology, Yiwu Hospital (Yiwu, China) between 2009 and 2010 after written informed consent was obtained from every participant. Clinical information was retrieved from patient records.
Immunohistochemistry (IHC) analysis
Paraffin-embedded tissues were cut into 5-μm thickness sections, which were de-paraffinized, rehydrated, and subjected to IHC analysis with anti-TRIM14 antibody (Abcam, Cambridge, MA, USA; ab185349) as previously described. Twelve non-cancerous tissue samples were also stained as controls. IHC assessment was conducted by two investigators independently. The staining index was evaluated as follows: staining index = staining intensity (SI) × percentage of positive cells (PP). The SI was determined as 0, negative; 1, weak; 2, moderate; 3, strong. PP was classified as 0, <5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; 4, >75%.
Patients were classified into two groups (TRIM14 low expression and TRIM14 high expression) based on the staining index. The cut-off was set at 3.
Cell culture
Human CRC cell lines LoVo, HT-29, and SW620 (Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China) were cultured in RPMI-1640 media containing 10% fetal bovine serum (Hyclone, Rockford, IL, USA) and antibiotics and maintained at 37°C and 5% CO 2 .
RNA interference-mediated knockdown of TRIM14 and overexpression of TRIM14 or PTEN Lentiviral plasmids expressing control short hairpin RNA (shRNA) (shNC) or TRIM14 shRNAs (shTRIM14-1, 2, 3), and TRIM14 or PTEN complementary DNAs (cDNAs) were constructed, and lentiviruses were produced as previously described. 22 
Western blot analysis
Cells were extracted in RIPA buffer with protease inhibitor cocktail (Beyotime, Shanghai, China 
Real-time PCR analysis
Cells were lysed with Trizol reagent (Invitrogen Carlsbad, CA, USA) to isolate total RNA as per the manufacturer's protocol. The concentration and quality of RNA were measured by NanoDrop spectrophotometer (ND-1000, Thermo Scientific, Rockford, IL, USA). Subsequently, complementary DNA (cDNA) was synthesized using total RNA and cDNA synthesis kit (Thermo Fisher), and then used as a template for real-time PCR analysis. Realtime PCR analysis was carried out using SYBR Green qPCR Master Mixes (Thermo Fisher) and ABI 7300 system (Applied Biosystem, Foster City, CA, USA) with GAPDH as an internal control. The oligonucleotides used as PCR primers were: PTEN, 5ʹ-TCAGGCGAGGGA GATGAGAG −3ʹ and 5ʹ-CAGGAGAAGCCGAGGAAG AG −3ʹ; Bcl-2, 5ʹ-GCAGTGTGGTCTCCGAATGTC −3ʹ and 5ʹ-CATTGCCTCTCCTCACGTTCC −3ʹ; Cyclin D1, 5ʹ-GCTGCGAAGTGGAAACCATC −3ʹ and 5ʹ-CCTC CTTCTGCACACATTTGAA −3ʹ; p27, 5ʹ-GCTTGCCC GAGTTCTACTAC −3ʹ and 5ʹ-GCAGGTCGCTTCCT TATTCC −3ʹ; GAPDH, 5ʹ-CACCCACTCCTCCACC TTTG-3ʹ and 5ʹ-CCACCACCCTGTTGCTGTAG −3ʹ.
Immunofluorescence staining
After washing with PBS, HT-29 cells cultured on coverslips were fixed with 4% paraformaldehyde at room temperature for 30 mins. To permeabilize cells and block non-specific protein-protein interactions, cells were incubated with 1% BSA and 10% normal goat serum in PBS-0.1% Tween for 1 hr. After probing with anti-PTEN (Abcam; ab79156; dilution: 1:100) and anti-TRIM14 (Invitrogen; PA5-62761; dilution: 1:200) antibodies overnight at 4°C, cells were labeled with Alexa Fluor 488 goat anti-rabbit IgG (H+L) (Beyotime; A0423; dilution: 1:500) and Alexa Fluor 555 donkey antimouse IgG (H+L) (Beyotime; A0460; dilution: 1:500) antibodies for 1 h at room temperature. Nuclei were then stained with 4, 6-diamino-2-phenylindole (DAPI; Beyotime), and cells were visualized with a fluorescence microscope.
Immunoprecipitation
Cells were lysed with RIPA buffer as described above. The supernatant was incubated with anti-PTEN (Cell Signaling Technology; #9552) or control IgG antibodies at 4°C for 2 hrs, followed by incubation with protein A agarose beads (Roche) at 4°C for another 1 hr. After washing with RIPA buffer three times, the protein was subjected to Western blotting analysis with anti-ubiquitin (Abcam; Ab7780) antibody.
Statistical analysis
The relationship between TRIM14 expression and clinicopathological features, and prognostic variables were analyzed by Fisher's exact test and log-rank test, respectively. ANOVA and Student's t-test were used to evaluate in vitro and in vivo experiments, respectively. Data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism software (La Jolla, CA, USA). P-value less than 0.05 was considered statistically significant.
Results
Increased TRIM14 expression was correlated with poor CRC patient prognosis
To determine the association between TRIM14 and clinicopathological characteristics, 74 CRC tissues were subjected to IHC staining with an antibody against TRIM14.
Of the 74 CRC tissues, 53 (71.6%) cases with more than 25% of the positive-stained cells were defined as TRIM14 high expression ( Figure 1A ). As shown in Table 1 , TRIM14 expression was significantly correlated with tumor size (P=0.0023) and clinical stage (P=0.0377), while no significant association between TRIM14 expression and other parameters, such as age, gender, and metastasis was observed. According to Kaplan-Meier analysis and log-rank test, CRC patients with high TRIM14 expression had shorter overall survival time (P=0.0060), as shown in Figure 1B . These data highlight a relationship between TRIM14 expression and CRC patient prognosis.
TRIM14 expression affected proliferation of CRC cells
Given that TRIM14 expression was significantly correlated with tumor size, we then explored the potential roles of TRIM14 in CRC cell proliferation by knocking down TRIM14 in HT-29 and SW620 cells using TRIM14 shRNA, or by overexpressing TRIM14 in LoVo cells by lentiviral infection as previously described. 22 TRIM14 protein expression was assessed by Western blotting at 48 hrs post-lentiviral infection. As shown in Figure 2A , TRIM14 protein levels were nearly abolished in cells with shTRIM14-1. Hence, this shRNA was used in the subsequent experiments. Similarly, LoVo cells with pLVX-TRIM14 infection displayed elevated protein levels of TRIM14, as shown in Figure 2B . To determine CRC cell proliferation, we performed CCK-8 assays at 24, 48, and 72 hrs post-viral infection. Compared to the control, HT-29 and SW620 cells with shTRIM14 displayed remarkably lower proliferation. On the other hand, LoVo cells with pLVX-TRIM14 infection showed notably higher proliferation ( Figure 2C ). Together, these data demonstrate a pro-proliferative function of TRIM14 in CRC.
TRIM14 regulated apoptosis of CRC cells
To elucidate the role of TRIM14 in cell apoptosis, Annexin V assay and flow cytometry analysis were performed. The results showed that early apoptotic rates were significantly increased in HT-29 and SW620 cells with shTRIM14 compared to control cells ( Figure 3A ), whereas opposite effects were seen in LoVo cells with pLVX-TRIM14 infection ( Figure 3B ). Hence, our results indicate an inhibitory effect of TRIM14 on CRC cell apoptosis.
Knockdown of TRIM14 affected cell proliferation and apoptosis of CRC cells in vivo
To further investigate the effects of TRIM14 knockdown on CRC tumor growth in vivo, HT-29 cells stably expressing shTRIM14 or shNC were subcutaneously injected into nude mice. As shown in Figure 4A , xenograft tumors generated from cells with shTRIM14 displayed slower growth than those formed in cells with shNC. On Day 33, tumor volume was significantly lower in the shTRIM14 group than in shNC group ( Figure 4B ). IHC ( Figure 4C ) analysis also revealed a low percentage of Ki67-positive cells in the shTRIM14 group. Together, these data indicate that TRIM14 may serve as an oncogene in CRC in vivo.
TRIM14 regulated PTEN/AKT signaling
The AKT pathway is critical for the oncogenesis of CRC. 17 Given the report that TRIM14 overexpression in osteosarcoma cells activated the AKT signaling pathway, we examined the protein levels of PTEN, p-AKT AKT, and downstream effectors of the AKT pathway (BCl-2, 23 Cyclin D1, 24 and p27
25
) in CRC cells with TRIM14 knockdown by Western blotting. Interestingly, TRIM14 knockdown suppressed the levels of p-AKT, Bcl-2, and Cyclin D1, but enhanced the levels of PTEN and p27 ( Figure 5A ). On the contrary, TRIM14 overexpression displayed the reverse effects ( Figure 5B ).
Real-time PCR analysis showed that TRIM14 knockdown had similar effects on the mRNA expression of Bcl-2, Cyclin D1, and p27. Notably, we observed that the PTEN mRNA was not affected by TRIM14 overexpression or knockdown ( Figure 5C and D) . As most TRIM family proteins have E3 ubiquitin ligase activity, 7 we speculated that TRIM14 may increase PTEN ubiquitination. Using TRIM14 and PTEN antibodies, we performed immunofluorescence staining in LoVo cells. As shown in Figure 5E , TRIM14 and PTEN localized in the cytoplasm and membrane, suggesting that TRIM14 may form a complex with PTEN. PTEN ubiquitination was also assessed in LoVo cells that were infected with pLVX or pLVX-TRIM14. As shown in Figure 5F , PTEN ubiquitination was increased by TRIM14 overexpression. Collectively, these data suggest that TRIM14 regulates PTEN expression via post-translational modification.
Overexpression of PTEN suppressed TRIM14-mediated CRC cell proliferation
To determine whether PTEN/AKT was involved in TRIM14-induced proliferation of CRC cells, we examined the growth ability of LoVo cells overexpressing TRIM14 and PTEN. As indicated in Figure 6 , PTEN overexpression inhibited the pro-proliferative effects of TRIM14. Hence, these data demonstrate that PTEN/AKT pathway contributes to the functions of TRIM14 in promoting CRC cell proliferation.
Discussion
The TRIM protein family is known to contain more than 70 members and most of them participate in numerous biological processes, such as innate immune response, cell proliferation, apoptosis, and invasion. gulation and oncogenic functions of other TRIM proteins, such as TRIM24 27, 28 and TRIM29 29, 30 have been reported in CRC. Recently, we have reported that TRIM14 mRNA levels were elevated in CRC tissues. 22 In the current study, IHC analysis confirmed the above findings at the translational level. Further, our data suggested that elevated expression of TRIM14 in CRC tissues was closely related to the aggressive clinicopathological characteristics and poor patient prognosis (Figure 1 ). TRIM14 knockdown inhibited CRC cell proliferation and promoted apoptosis, while TRIM14 overexpression had the opposite effects (Figures 2-4 ). These data, combined with our previous study, 22 demonstrated the oncogenic effects of TRIM14 in CRC, which were consistent with the findings in other types of human malignancies.
12-15
We also explored the possible mechanism through which TRIM14 induced proliferation and inhibited apoptosis of CRC cells. It has been well established that AKT signaling is critical in the tumorigenesis and development of cancer by regulating cell proliferation, apoptosis, and migration. 16 AKT phosphorylation predicts poor disease-free survival in stage II CRC patients. 31 CRC cells with AKT overexpression were highly proliferative and invasive. 18 The blockage of the AKT pathway possesses anti-tumorigenic effects in CRC cells and provides a potential strategy for CRC treatment. [32] [33] [34] As a negative regulator of the AKT pathway, PTEN is downregulated in CRC 20 and serves as a tumor suppressor in CRC. 21 Herein, consistent with earlier findings, TRIM14 overexpression increased p-AKT levels and decreased PTEN levels in CRC cells ( Figure 5 ). The AKT pathway exerts its functions by regulating multiple downstream molecules, such as Cyclin D1, p27, and Bcl-2. Cyclin D1 is an important factor responsible for G1/S transition, 24 and p27 is an inhibitor of Cyclindependent kinase, 25 while Bcl-2 is a well-known anti-apoptotic factor. 23 In the present study, TRIM14 knockdown resulted in reduced Cyclin D1 and Bcl-2 levels but enhanced p27 levels in CRC cells. Opposite effects were seen in CRC cells with TRIM14 overexpression (Figure 5 ). Notably, overexpression of PTEN reversed the pro-proliferative effects of TRIM14 on CRC cells ( Figure 6 ). Accordingly, these data indicate that TRIM14 overexpression activates the AKT pathway, which contributes to the highly proliferative phenotype of CRC cells. Lastly, it has been reported that polyubiquitination of PTEN caused its retention in the cytoplasm and degradation. 35 TRIM27 is able to promote PTEN polyubiquitination and thus inhibits its phosphatase activity. 36 In the current study, TRIM14 levels affected PTEN expression at translational level, but not at the transcriptional level ( Figure 5C and D). Further, we found that TRIM14 may form a complex with PTEN and promoted PTEN ubiquitination ( Figure 5E and F), which was similar to that observed for TRIM27. However, TRIM14 lacks a RING domain, which is usually required for E3 ubiquitin ligase activity on TRIM family proteins. 7 The precise mechanism of how TRIM14 affected PTEN ubiquitination requires further investigation. In summary, we reported that elevated expression of TRIM14 in clinical CRC samples was correlated with patient prognosis. Knockdown of TRIM14 suppressed the aggressiveness of CRC cells by modulating the PTEN/AKT signaling pathway. TRIM14 formed a complex with PTEN and induced PTEN ubiquitination. These findings advance our knowledge of CRC progression and suggest that TRIM14 may emerge as an attractive therapeutic target for CRC. 
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